XIDX
CPRO
Market cap206mUSD
Nov 12, Last price
62.00IDR
Name
Central Proteina Prima Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Central Proteina Prima Tbk, together with its subsidiaries, operates as an integrated aquaculture shrimp and food producer company in Indonesia, India, Vietnam, China, Japan, the United States, Canada, the United Kingdom, Belgium, France, the Netherlands, Germany, and New Zealand. The company operates through Feeds, Food Products, and Others segments. It engages in the industry, livestock and agriculture, farming, hatchery, and trading and services, as well as production and trading of shrimp, fish feeds and pet food. The company also offers shrimp feed, fish feed, cat food, dog food, fish food, bird food, rabbit food, probiotic products, fish additives, disinfectants, fish hatchery, shrimp hatchery, medicines for shrimp and fish, and probiotic for shrimp medicines, as well as is involved in the cold storage and trading of shrimp, and an investment holding business. The company was formerly known as PT Central Proteinaprima Tbk and changed its name to PT Central Proteina Prima Tbk in June 2014. The company was incorporated in 1980 and is headquartered in Jakarta Selatan, Indonesia.
Key people
Hendri Laiman
President Director · since 2021
Franciscus Affandy
Vice President Commissioner
Saleh Yu
Vice President Director · since 2015
Arman Zakaria Diah
Director · since 2021
Budy Powito
Director · since 2021
Fredy Robin Sumendap
Director · since 2019
Arianto Yohan
Director · since 2016
Armand Ardika
Corporate Secretary · since 2011
Commissioner · since 2018
Christopher Michael Nacson
Commissioner · since 2018
Djoko Muhammad Basoeki
Independent Commissioner · since 2012
Toto Winanto
Independent Commissioner · since 2019
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||